Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page
- Check2 days agoChange DetectedMinor visual/layout updates to the Study Details page; core content such as objectives, eligibility criteria, outcomes, and locations remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check9 days agoNo Change Detected
- Check31 days agoChange Detected- Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check38 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page has been updated to reflect an increase in study locations from 55 to 58, and the last update date has been revised to August 2025.SummaryDifference2%

- Check67 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility names and locations, while also removing several previous location entries and medical conditions. Notably, the revision number has been updated from v2.16.12 to v3.0.0.SummaryDifference12%

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.